Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients At High Cardiovascular Risk: CLEAR OUTCOME
Statins have been proven to lower cardiovascular events. However, some patients report adverse events from statins, most commonly muscle-related symptoms, and cannot take statins. Alternative therapies are needed to lower LDL-C in patients unable to meet guideline treatment goals. Bempedoic acid is an ATP citrate lyase inhibitor that targets cholesterol synthesis upstream of HMG-CoA reductase, the enzyme targeted by statins. It has been approved as a treatment for LDL-C lowering since 2020 based on studies that have shown LDL-C reduction of 15-25%.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Leslie Cho Tags: Pathophysiology of Atherosclerosis Source Type: research
More News: Alternative and Complementary Therapies | Cardiology | Cardiovascular | Cholesterol | Complementary Medicine | Heart | Lipidology | Statin Therapy | Study